Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Eit Pharma Inc. currently has 1 pending office action. This prosecution activity occurs within the Biotechnology & Pharmaceuticals technology area. The presence of 1 pending office action indicates a specific point of engagement with the patent office at this time.
The data shows 1 distinct examiner and 1 distinct art unit associated with the portfolio. This indicates a singular channel for prosecution, where all current results depend on the findings within that 1 distinct art unit. CARTER, SANDRA DILLAHUNT is the busiest examiner for the company and is currently handling 1 pending office action.
As the only examiner listed, the specific approach of CARTER, SANDRA DILLAHUNT to the Biotechnology & Pharmaceuticals field is the central factor for the company's pending matters. The 1 pending office action requires a strategy that addresses the individual preferences of this 1 distinct examiner. This concentrated structure allows the applicant to focus resources on a single set of examiner requirements within the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760279 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | CARTER, SANDRA DILLAHUNT | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760279 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | CARTER, SANDRA DILLAHUNT | 34d |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17760279 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | CARTER, SANDRA DILLAHUNT | 1674 | §103§112Other | Non-Final OA | 34d | Pending | Aug 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial